WCN26-9488 Cardiorenal protective effect of SGLT2i empagliflozin in a novel mouse model of uremic cardiomyopathy via regulating the Nrf2-mediated oxidative stress

Read full text Summarise with VIRAT
Authors: Yeqing Xie, Shi Cheng, Jiarui Xu, Xiaoqiang Ding
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Uremic cardiomyopathy (UCM), characterized by left ventricular hypertrophy, myocardial fibrosis, and predominant diastolic dysfunction, is a major contributor to cardiovascular mortality in end-stage renal disease (ESRD). Progress in mechanistic and therapeutic research has been hindered by the lack of preclinical models that faithfully reproduce the integrated cardiac and renal phenotype observed in patients. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal protective effects in chronic kidney disease beyond glycemic control; however, their therapeutic relevance to UCM remains largely unexplored.

Fields of Study & Subjects

Dialysis and Renal Disease Management Chronic Kidney Disease and Diabetes Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104288–104288
Publication date
25 March 2026
Language
EN